好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Hypertensive Microangiopathy as the Cause of Deep Cerebellar Intracerebral Hemorrhage
Cerebrovascular Disease and Interventional Neurology
P2 - Poster Session 2 (11:45 AM-12:45 PM)
5-023

To determine whether hypertensive cerebral small vessel disease (HTN-cSVD) is the underlying microangiopathy of deep (white matter, deep nuclei, cerebellar peduncle) cerebellar intracerebral hemorrhage (cICH).

Superficial (gray matter, vermis) cICH is associated with strictly lobar supratentorial cerebral microbleeds (CMBs)—a marker for cerebral amyloid angiopathy. We hypothesized that left ventricular hypertrophy (LVH), a marker for HTN-cSVD, and non-hemorrhagic markers of HTN-cSVD (peri-basal ganglia [BG] white matter hyperintensity [WMH] pattern, deep lacunes, and severe BG enlarged perivascular spaces [EPVS]) would be associated with deep vs. superficial cICH.

 

Brain MRIs from consecutive non-traumatic ICH patients admitted to a referral center (2003 to 2019) were reviewed for CMBs and non-hemorrhagic markers. Clinical risk factors, LVH, and neuroimaging markers were compared between deep and superficial cICH patients in univariate/multivariable models.

Of 1,791 patients with ICH, 129 (7%) were found to have cICH (mean age 73±12 years, 46% female). Of these, 83 (64%) had deep cICH and 46 (36%) had superficial cICH. Hypertension (94% vs. 67%, p < 0.01) and LVH (60% vs. 28%, p < 0.01) were more common among patients with deep cICH. Among those with MRIs (74%), the frequency of peri-BG WMH pattern (24% vs. 5%, p = 0.02), deep lacunes (59% vs. 14%, p < 0.01), severe BG EPVS (27% vs. 3%, p < 0.01), deep CMBs (51% vs. 16%, p < 0.01), and mixed-location CMBs (37% vs. 11%, p < 0.01) was greater among deep cICH patients. When entered into a multivariable regression, LVH (OR 3.10, 95% CI [1.07–8.97], p = 0.04) and deep lacunes (OR 4.38, 95% CI [1.25–15.31], p = 0.02) remained significantly associated with deep cICH.

Because supratentorial HTN-cSVD markers are common in deep cICH, and deep lacunes and LVH are independently associated with deep cICH, it is likely that HTN-cSVD is the underlying microangiopathy of deep cICH.

Authors/Disclosures
Alvin Das, MD
PRESENTER
Dr. Das has nothing to disclose.
Avia Abramovitz Ms. Abramovitz has nothing to disclose.
Elif Gokcal Elif Gokcal has nothing to disclose.
Ofer Rotschild Ofer Rotschild has nothing to disclose.
Marco Pasi No disclosure on file
Robert W. Regenhardt, MD, PhD Dr. Regenhardt has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genomadix. Dr. Regenhardt has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Rapid Medical. Dr. Regenhardt has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Johnson and Bell Trial Lawyers. Dr. Regenhardt has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for Buckley, Theroux, Kline, & Cooley Trial Lawyers. The institution of Dr. Regenhardt has received research support from National Institutes of Health. The institution of Dr. Regenhardt has received research support from Society of Vascular and Interventional Neurology. The institution of Dr. Regenhardt has received research support from Heitman Foundation.
Joshua Goldstein (Massachusetts General Hospital) Joshua Goldstein has received personal compensation in the range of $500-$4,999 for serving as a Consultant for CSL Behring. The institution of Joshua Goldstein has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Octapharma. Joshua Goldstein has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Astrazeneca. The institution of Joshua Goldstein has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Takeda. The institution of Joshua Goldstein has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Octapharma. Joshua Goldstein has stock in NControl. Joshua Goldstein has stock in Cayuga. The institution of Joshua Goldstein has received research support from Pfizer. The institution of Joshua Goldstein has received research support from Takeda.
Anand Viswanathan, MD (Massachusetts General Hospital) Dr. Viswanathan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alnylam Pharmaceuticals. Dr. Viswanathan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Viswanathan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche Pharmaceuticals.
Jonathan Rosand, MD (Massachusetts General Hospital) Dr. Rosand has received personal compensation for serving as an employee of Massachusetts General Hospital. Dr. Rosand has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eli Lilly and Co. Dr. Rosand has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Elsevier. The institution of Dr. Rosand has received research support from NIH. The institution of Dr. Rosand has received research support from American Heart Association. Dr. Rosand has received personal compensation in the range of $0-$499 for serving as a Peer reviewer with National Institutes of Health. Dr. Rosand has a non-compensated relationship as a Trustee with Columbia University that is relevant to AAN interests or activities.
Steven M. Greenberg, MD, PhD, FAAN Dr. Greenberg has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Bayer. Dr. Greenberg has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Bristol Myers Squib. The institution of Dr. Greenberg has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alnylam. Dr. Greenberg has received research support from National Institutes of Health. Dr. Greenberg has received publishing royalties from a publication relating to health care.
Edip M. Gurol, MD (Massachusetts General Hospital) The institution of Dr. Gurol has received research support from NIH/NINDS. The institution of Dr. Gurol has received research support from Boston Scientific Corporation. The institution of Dr. Gurol has received research support from AVID (a wholly owned subsidiary of Eli Lilly). The institution of Dr. Gurol has received research support from Pfizer.